DNL343   Click here for help

GtoPdb Ligand ID: 12940

Synonyms: DNL-343
Compound class: Synthetic organic
Comment: DNL343 is an investigational small molecule eIF2B activator [1]. It blocks activation of the integrated stress response (ISR), a biological process that plays a role in driving neurodegeneration in diseases such as ALS/MND and vanishing white matter disease (VWMD). DNL343 was designed to address ISR-mediated neurodegeneration.
The HGNC lists 4 human genes for eIF2B subunits (EIF2B1-EIF2B4).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 81.51
Molecular weight 457.83
XLogP 3.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=C(C=CC(=C1)OCC(=O)NC23CC(C2)(C3)C4=NN=C(C5CC(C5)OC(F)(F)F)O4)Cl
Isomeric SMILES C=1C=C(OCC(NC23CC(C=4OC(C5CC(OC(F)(F)F)C5)=NN4)(C2)C3)=O)C=CC1Cl
InChI InChI=1S/C20H19ClF3N3O4/c21-12-1-3-13(4-2-12)29-7-15(28)25-19-8-18(9-19,10-19)17-27-26-16(30-17)11-5-14(6-11)31-20(22,23)24/h1-4,11,14H,5-10H2,(H,25,28)
InChI Key IKPNRMYDOSNVAU-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
DNL343 is in clinical development for ALS.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04297683 HEALEY ALS Platform Trial - Master Protocol Phase 2/Phase 3 Interventional Massachusetts General Hospital
NCT05842941 HEALEY ALS Platform Trial - Regimen G DNL343 Phase 2/Phase 3 Interventional Massachusetts General Hospital
NCT04268784 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers Phase 1 Interventional Denali Therapeutics Inc.